His primary areas of investigation include Antibody, Antigen, Cytotoxic T cell, Immunology and CD3. CD19 is the focus of his Antibody research. His work carried out in the field of Antigen brings together such families of science as Molecular biology and Pathology.
His research ties Immunotherapy and Cytotoxic T cell together. Within one scientific family, Peter Kufer focuses on topics pertaining to Cytotoxicity under CD3, and may sometimes address concerns connected to Chinese hamster ovary cell. His studies in T cell integrate themes in fields like Blinatumomab and CD8.
Peter Kufer mainly investigates Antibody, Antigen, T cell, Immunology and Molecular biology. His Antibody research is multidisciplinary, incorporating perspectives in Cancer research and CD3. His Cancer research study combines topics from a wide range of disciplines, such as Cancer cell, Epithelial cell adhesion molecule, Prostate cancer and Immunotherapy.
His research on Antigen also deals with topics like
His scientific interests lie mostly in Antibody, T cell, Cancer research, CD3 and Blinatumomab. His biological study spans a wide range of topics, including Cell biology, Cell and In vitro, Cytotoxicity. The T cell study combines topics in areas such as Ex vivo, Cytotoxic T cell, Molecular biology and Antigen.
His Cytotoxic T cell research integrates issues from Single-chain variable fragment and Virology. His Cancer research research includes themes of Immune checkpoint, Immunotherapy, Cancer cell and Castration resistant, Prostate cancer. His CD3 study incorporates themes from Binding domain, Bispecific antibody and CD33.
His main research concerns Blinatumomab, T cell, Internal medicine, Cancer research and Immunology. His Blinatumomab research is included under the broader classification of CD19. His research investigates the link between T cell and topics such as Ex vivo that cross with problems in Immunodeficiency, Virology, Viral load, Cytotoxic T cell and Single-chain variable fragment.
The various areas that Peter Kufer examines in his Cancer research study include CD3, Castration resistant, Prostate cancer, Poor prognosis and Antibody. His research integrates issues of Lineage, Phases of clinical research and Relapse free survival in his study of Immunology. Peter Kufer has researched Immune system in several fields, including Tumor necrosis factor alpha, Interferon, Antigen and Cytotoxicity.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp;Peter Kufer;Nicola Gökbuget;Mariele Goebeler.
Journal of Clinical Oncology (2011)
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Ralf Bargou;Eugen Leo;Gerhard Zugmaier;Matthias Klinger.
A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity
Matthias Mack;Gert Riethmuller;Peter Kufer.
Proceedings of the National Academy of Sciences of the United States of America (1995)
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
Anja Löffler;Peter Kufer;Peter Kufer;Peter Kufer;Ralf Lutterbüse;Ralf Lutterbüse;Ralf Lutterbüse;Florian Zettl;Florian Zettl;Florian Zettl.
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
Matthias Klinger;Christian Brandl;Gerhard Zugmaier;Youssef Hijazi.
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp;Nicola Gökbuget;Gerhard Zugmaier;Evelyn Degenhard.
Novel method for the production of anti-human antigen receptors and uses thereof
Peter Kufer;Tobias Raum.
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
Torsten Dreier;Grit Lorenczewski;Christian Brandl;Patrick Hoffmann.
International Journal of Cancer (2002)
Blinatumomab: a historical perspective.
Dirk Nagorsen;Peter Kufer;Patrick A. Baeuerle;Ralf Bargou.
Pharmacology & Therapeutics (2012)
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.
Sonja Offner;Robert Hofmeister;Andrea Romaniuk;Peter Kufer.
Molecular Immunology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: